# Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer

> **NCT01023204** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 68 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01023204
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2005-07
- **Final completion:** 2005-07
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2010-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01023204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01023204, "Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01023204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*